Claims
- 1. A method of treating osteoarthritis in mammals comprising administering to a mammal in need of such treatment an effective amount for treatment of osteoarthritis of a member selected from the group consisting of a poly-N-acetyl-D-glucosamine (poly-NAG), a pharmaceutically acceptable derivative of poly-NAG, and mixtures thereof.
- 2. The method according to claim 1, wherein said material is said poly-N-acetyl-D-glucosamine (poly-NAG).
- 3. The method according to claim 1, wherein said pharmaceutically acceptable derivative of poly-NAG is selected from the group consisting of hydroxy lower alkyl poly-NAG, carboxy lower alkyl poly-NAG, a salt of carboxy lower alkyl poly-NAG, lower alkyl poly-NAG, poly-NAG acetate, poly-NAG nitrate, poly-NAG citrate, and poly-NAG phosphate.
- 4. The method according to claim 1, which comprises administering said effective amount orally.
- 5. The method according to claim 1, which comprises administering said effective amount by injection.
- 6. The method according to claim 4, wherein said effective amount is between about 100 and about 10,000 mg/day.
- 7. The method according to claim 5, wherein said effective amount is between about 100 and about 10,000 mg/day.
- 8. The method according to claim 1, wherein said mammal is a human.
- 9. A method of alleviating the symptoms of osteoarthritis in mammals comprising administering to a mammal suffering from such symptoms a therapeutically effective amount of a material selected from the group consisting of a poly-N-acetyl-D-glucosamine (poly-NAG), a pharmaceutically acceptable derivative of poly-NAG, and mixtures thereof, to alleviate at least one of the symptoms of osteoarthritis.
- 10. The method according to claim 9, wherein said material is said poly-N-acetyl-D-glucosamine (poly-NAG).
- 11. The method according to claim 9, wherein said pharmaceutically acceptable derivative of poly-NAG is selected from the group consisting of hydroxy lower alkyl poly-NAG, carboxy lower alkyl poly-NAG, a salt of carboxy lower alkyl poly-NAG, lower alkyl poly-NAG, poly-NAG acetate, poly-NAG nitrate, poly-NAG citrate, and poly-NAG phosphate.
- 12. The method according to claim 9, which comprises administering said effective amount via the oral route.
- 13. The method according to claim 12, wherein said effective amount is between about 100 and about 10,000 mg/day.
- 14. The method according to claim 9, which comprises administering said effective amount in a solid dosage form.
- 15. The method according to claim 9, which comprises administering said effective amount by injection.
- 16. The method according to claim 9, wherein said mammal is a human.
- 17. A pharmaceutical dosage form comprising a material selected from the group consisting of a poly-N-acetyl-D-glucosamine (poly-NAG), a pharmaceutically acceptable derivative of poly-NAG, and mixtures thereof.
- 18. The pharmaceutical dosage form according to claim 17, wherein said material is said poly-N-acetyl-D-glucosamine (poly-NAG).
- 19. The pharmaceutical dosage form according to claim 17, wherein said pharmaceutically acceptable derivative of poly-NAG is selected from the group consisting of hydroxy lower alkyl poly-NAG, carboxy lower alkyl poly-NAG, a salt of carboxy lower alkyl poly-NAG, lower alkyl poly-NAG, poly-NAG acetate, poly-NAG nitrate, poly-NAG citrate, and poly-NAG phosphate.
- 20. The pharmaceutical dosage form of claim 17, wherein said dosage form is a solid oral dosage form selected from the group consisting of a tablet, a capsule, a pellet and a powder.
- 21. The pharmaceutical dosage form of claim 17, wherein said dosage form is a suspension for oral administration.
- 22. The pharmaceutical dosage form of claim 17, wherein said dosage form is an injection.
Parent Case Info
[0001] This application claims priority pursuant to 35 U.S.C. §119 from U.S. Provisional Application Ser. No. 60/032,855 filed Dec. 13, 1996, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60032855 |
Dec 1996 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09467252 |
Dec 1999 |
US |
Child |
09780237 |
Feb 2001 |
US |
Parent |
08990161 |
Dec 1997 |
US |
Child |
09467252 |
Dec 1999 |
US |